Oral VK2735
Sources
registry, as of 2026-10-16Stale
https://clinicaltrials.gov/study/NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Viking Therapeutics, Inc.. Enrollment 560. Conditions Weight Loss. This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
ClinicalTrials.gov NCT07868939 protocol and results modules
registry, as of 2026-10-16Stale
https://clinicaltrials.gov/study/NCT07868835
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Viking Therapeutics, Inc.. Enrollment 560. Conditions Weight Loss. This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
ClinicalTrials.gov NCT07868835 protocol and results modules
registry, as of 2025-10-06Stale
https://clinicaltrials.gov/study/NCT06828055
VK2735 for Weight Management Phase 2 (Venture Oral Dosing). Overall status COMPLETED. Phases PHASE2. Lead sponsor Viking Therapeutics, Inc.. Enrollment 280. Conditions Weight Loss. This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg
ClinicalTrials.gov NCT06828055 protocol and results modules
registry, as of 2026-09-24Stale
https://clinicaltrials.gov/study/NCT07838740
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities. Overall status RECRUITING. Phases PHASE1. Lead sponsor Viking Therapeutics, Inc.. Enrollment 270. Conditions Obese Adults. The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
ClinicalTrials.gov NCT07838740 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07868939
Diabetes Mellitus (T2DM) who are obese or overweight. VK2735 Oral VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily Placebo Comparator Placebo comparator administered orally once daily
NCT07868939 description or intervention text